Sterling is an Italian CDMO with 50 years of experience in API development and manufacturing, now evolving beyond traditional supply toward an integrated development partner. Today, we contribute not only to the production of active pharmaceutical ingredients, but to the design of their performance from the earliest stages of development.

Our capabilities span API development and manufacturing across multiple scales, particle engineering and pre-formulation — including micronization and solid-state control — as well as performance-driven generic development, with a strong focus on inhalation products. In the respiratory field, we work on optimizing API properties to meet defined target product profiles, supporting in vitro performance and consistency. We are also advancing new delivery approaches, including nasal platforms and nanoparticle-based solutions.

Our integrated analytical and regulatory expertise allows us to streamline development, reduce risk, and accelerate time to market.

At Sterling, quality is not a function, but a method applied across the entire value chain — enabling long-term partnerships and reliable outcomes.